<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330160</url>
  </required_header>
  <id_info>
    <org_study_id>2008_42/0907</org_study_id>
    <secondary_id>2008/API1901</secondary_id>
    <secondary_id>2009-A00141-56</secondary_id>
    <nct_id>NCT01330160</nct_id>
  </id_info>
  <brief_title>Study of Factors Influencing Post-stroke Dementia</brief_title>
  <acronym>strokdem</acronym>
  <official_title>Characterization of Clinical, Biological, Morphological and Pharmacological Factors Influencing Occurrence of Dementia or Cognitive Disorders After Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      If the risk of dementia occurrence after stroke is well known, few data exist about the
      factors influencing positively or negatively the developement of cognitive disorders or
      dementia. The aim of the study is so to determine prospectively the clinical, biological,
      lesional and pharmacological factors associated with post-stroke dementia by the long-term
      follow-up of a stroke patient cohort.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The STROKDEM study is based on the 5-year prospective follow-up of a population of 1100
      stroke patients without dementia. At inclusion in the cohort, main antecedents and risk
      factors, previous treatment and lifestyle, initial severity and etiology are recorded.
      Biological samples (for standard ans specialized analyses) and MRI are performed at 72h after
      stroke occurrence. Thereafter, patients are regularly (6 months, 12 months, 36 months, 60
      months) examined for clinical and cognitive assessment with biological samples and Magnetic
      Resonance Imaging. Patients with dementia will be compared to patients without stroke to
      identify, by logistic regression analysis and Cox model, the factors associated with dementia
      occurrence.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2010</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>dementia occurrence</measure>
    <time_frame>60 months</time_frame>
    <description>This evaluation will be based on a neurological and general clinical examination, and on the evaluation of activities of daily life using the Instrumental Activities Daily Life scale after an interview with the patient and his/her family.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>dementia occurrence and cognitive impairment</measure>
    <time_frame>6 months</time_frame>
    <description>This evaluation will be based on a neurological and general clinical examination, and on the evaluation of activities of daily life using the Instrumental Activities Daily Life scale after an interview with the patient and his/her family.
Impairment of some tests of cognitive battery without significant impairment in activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dementia occurrence and cognitive impairment</measure>
    <time_frame>12 months</time_frame>
    <description>This evaluation will be based on a neurological and general clinical examination, and on the evaluation of activities of daily life using the Instrumental Activities Daily Life scale after an interview with the patient ans his/her family.
Impairment of some tests of cognitive battery without significant impairment in activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dementia occurence and cognitive impairment</measure>
    <time_frame>36 months</time_frame>
    <description>This evaluation will be based on a neurological and general clinical examination, and on the evaluation of activities of daily life using the Instrumental Activities Daily Life scale after an interview with the patient ans his/her family.
Impairment of some tests of cognitive battery without significant impairment in activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive impairment</measure>
    <time_frame>36 months</time_frame>
    <description>Impairment of some tests of cognitive battery without significant impairment in activities of daily living</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Cerebrovascular Disorders</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>cohort of stroke patients</arm_group_label>
    <description>patients, over 40 years old and without dementia, displaying an hemorrhagic or an ischemic stroke, with a sus-tentorial localization, and included 72h before the onset of symptoms</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      standard biological parameters (ionogram, blood count, glycemia, lipids, renal function,
      vitamin B12, thyroid hormones, homocysteinemia), specialized biology (inflammation,
      oxidative, vascular biomarkers ; amyloid and tau markers), genotype (apolipoprotein E,
      apolipoprotein C, kinesin, Angiotensin Converting Enzyme...).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients without dementia displaying an hemispheric ischemic or hemorrhagic stroke
        hospitalized during the 72h following the beginning of stroke
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients &gt; 40 years olds

          -  hemispheric stroke

          -  stroke dating from less 72h

          -  IQ-code &lt; 64

          -  patient (or his family) given an informed consent

        Exclusion Criteria:

          -  non hemispheric stroke

          -  malformative intracranial hemorrhage

          -  traumatic intracranial hemorrhage

          -  subarachnoidal hemorrhage

          -  contra-indication to MRI

          -  patients unable to answer to cognitive battery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Regis Bordet, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Lille University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Regis Bordet, MD PhD</last_name>
    <phone>+33 (0)3 20 44 54 49</phone>
    <email>regis.bordet@chru-lille.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Didier Leys, MD PhD</last_name>
    <phone>+33 (0)3 20 44 68 14</phone>
    <email>dleys@chru-lille.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amiens University Hospital</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lille University Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59045</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Régis Bordet, MD PhD</last_name>
      <phone>+33 (0)3 20 44 54 49</phone>
      <email>regis.bordet@chru-lille.fr</email>
    </contact>
    <contact_backup>
      <last_name>Didier Leys, MD PhD</last_name>
      <phone>+33 (0)3 20 44 68 14</phone>
      <email>dleys@chru-lille.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Régis Bordet, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier Leys, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hilde Henon, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucas Christian, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Girot Marie, MD phD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cordonnier Charlotte, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederic Dumont, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bodenant Marie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence Pasquier, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie Bombois, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Anne Mackowiak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Deramecourt, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion Paulin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence Lebert, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Hannequin, MD PhD</last_name>
      <email>Didier.Hannequin@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Didier Hannequin, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evelyne Guegan-Massardier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aude Triquenot-Bagan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2010</study_first_submitted>
  <study_first_submitted_qc>April 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>Brain ischemia</keyword>
  <keyword>Intracranial hemorrhage</keyword>
  <keyword>Dementia, Vascular</keyword>
  <keyword>Alzheimer's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cerebrovascular Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

